Aberrant O-glycosylation genes and miR-21-5p targets define a molecular signature of tumor aggressiveness in triple-negative breast cancer

Clicks: 23
ID: 318692
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #40 of 72 articles by views in glycobiology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Aberrant O-glycosylation and miRNA dysregulation are established features of tumor aggressiveness, particularly in triple-negative breast cancer (TNBC). Using a Cosmc-silenced 4 T1 murine model (Tn+), characterized by truncated O-glycans and enhanced metastatic potential, tissue and serum miRNA profiling identified miR-21-5p as a circulating marker associated with the Tn+ phenotype. Transcriptomic analysis revealed that miR-21-5p targets multiple tumor suppressor genes, including Btg2, Spry1, Tbx2, Rhob, and Dusp8, suggesting its involvement in epithelial–mesenchymal transition and immune modulation. Integrative single-cell RNA sequencing (scRNA-seq) of the 4 T1 tumor microenvironment revealed distinct cellular clusters with inverse expression patterns of GALNT enzymes (involved in Tn synthesis) and miR-21-5p target genes, defining Tn+-like and Tn—like subpopulations. Translating these findings to human breast cancer (TCGA-BRCA), a prognostic model combining clinical variables (age, metastasis, PAM50 subtype) with three-gene expression (OLR1, PCSK6, and GALNT6) significantly improved patient risk stratification (P = 0.015). By integrating multi-omics analyses (scRNA-seq, TCGA) with an aggressive Tn+ TNBC model, this study defines a novel three-gene prognostic signature that links the glyco-miRNA axis to tumor aggressiveness, offering a promising tool for advanced patient stratification and the development of precision glyco-therapeutics.
Reference Key
openalex_W7165843909 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal glycobiology
Year 2026
DOI
10.1093/glycob/cwag046
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.